Keywords: sanofi, publishes, new, data, multaq, french, drug
Sanofi publishes new data on Multaq
Article | 08 September 2008
French drug major Sanofi-Aventis' anti-arrhythmic Multaq (dronedarone) significantly reduces ventricular rate in patients with permanent atrial fibrilation, according to a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
